Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: Impact of patient selection factors on outcome

Journal of Clinical Oncology

Volumn 23, Issue 12, 2005, Pages 2781-2788

  Stephenson, Andrew J ^a   Bosl, George J ^a   Motzer, Robert J ^a   Kattan, Michael W ^a   Stasi, Jason ^a   Bajorin, Dean F ^a   Sheinfeld, Joel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARAAORTIC LYMPH NODE; PATIENT INFORMATION; PATIENT SELECTION; PRIORITY JOURNAL; TESTIS CANCER; CANCER STAGING; DISEASE COURSE; LYMPHADENECTOMY; NEOPLASM; ORCHIECTOMY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TESTIS TUMOR; TREATMENT OUTCOME;

DISEASE PROGRESSION; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 18444391478     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.132     Document Type: Article

References (50)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Sheinfeld J: Nonseminomatous germ cell tumors of the testis: Current concepts and controversies. Urology 44:2-14, 1994
3. Donohue JP, Thornhill JA, Foster RS, et al: Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): Modifications of technique and impact on ejaculation. J Urol 149:237-243, 1993
4. Donohue JP, Thornhill JA, Foster RS, et al: Clinical stage B non-seminomatous germ cell testis cancer: The Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A: 1599-1604, 1995
5. Logothetis CJ, Swanson DA, Dexeus F, et al: Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: A follow-up of 50 patients. J Clin Oncol 5:906-911, 1987
6. Horwich A, Norman A, Fisher C, et al: Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. J Urol 151:72-77, 1994
7. Baniel J, Foster RS, Gonin R, et al: Late relapse of testicular cancer. J Clin Oncol 13: 1170-1176, 1995
8. George DW, Foster RS, Hromas RA, et al: Update on late relapse of germ cell tumor: A clinical and molecular analysis. J Clin Oncol 21: 113-122, 2003
9. Sheinfeld J: Late recurrence of testicular cancer. AUA News 6:12-14, 2001
10. Davis BE, Herr HW, Fair WR, et al: The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 152:111-113, 1994
11. Sheinfeld J, Rabbani F, Farivar-Mohseni H, et al: Elevated serum tumor markers prior to primary RPLND predicts clinical outcome and requirements for systemic chemotherapy in patients with PN1, N2 and N3 nonseminomatous germ cell tumor. Proc Am Soc Clin Oncol 18: 308a, 1999 (abstr 1184)
12. Rabbani F, Sheinfeld J, Farivar-Mohseni H, et al: Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: Pattern and prognostic factors for relapse. J Clin Oncol 19:2020-2025, 2001
13. McLeod DG, Weiss RB, Stablein DM, et al: Staging relationships and outcome in early stage testicular cancer: A report from the Testicular Cancer Intergroup Study. J Urol 145:1178-1183, 1991
14. Pizzocaro G, Zanoni F, Milani A, et al: Retroperitoneal lymphadenectomy and aggressive chemotherapy in nonbulky clinical stage II nonseminomatous germinal testis tumors. Cancer 53:1363-1368, 1984
15. Williams SD, Stablein DM, Einhorn LH, et al: Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433-1438, 1987
16. Socinski MA, Garnick MB, Stomper PC, et al: Stage II nonseminomatous germ cell tumors of the testis: An analysis of treatment options in patients with low volume retroperitoneal disease. J Urol 140:1437-1441, 1988
17. Vogelzang NJ, Fraley EE, Lange PH, et al: Stage II nonseminomatous testicular cancer: A 10-year experience. J Clin Oncol 1:171-178, 1983
18. Javadpour N, Young JD Jr: Prognostic factors in nonseminomatous testicular cancer. J Urol 135:497-499, 1986
19. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
20. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers: International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
21. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer Verlag, 2002
22. Kondagunta GV, Sheinfeld J, Mazumdar M, et al: Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 22:464-467, 2004
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer Verlag, 2000
25. Behnia M, Foster R, Einhorn LH, et al: Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. The Indiana University experience. Eur J Cancer 36:472-475, 2000
26. Weissbach L, Hartlapp JH: Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 146:1295-1298, 1991
27. Hermans BP, Sweeney CJ, Foster RS, et al: Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 163:1721-1724, 2000
28. Albers P, Siener R, Kliesch S, et al: Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: Results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21:1505-1512, 2003
29. Klepp O, Olsson AM, Henrikson H, et al: Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: Multivariate analysis of a prospective multicenter study-Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 8:509-518, 1990
30. Pizzocaro G, Monfardini S: No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. J Urol 131:677-680, 1984
31. Logothetis CJ, Samuels ML, Trindade A, et al: The growing teratoma syndrome. Cancer 50:1629-1635, 1982
32. Motzer RJ, Amsterdam A, Prieto V, et al: Teratoma with malignant transformation: Diverse malignant histologies arising in men with germ cell tumors. J Urol 159:133-138, 1998
33. Kollmannsberger C, Kuzcyk M, Mayer F, et al: Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 17:275-281, 1999
34. Bokemeyer C, Berger CC, Kuczyk MA, et al: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14: 2923-2932, 1996
35. Berger CC, Bokemeyer C, Schneider M, et al: Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A:2229-2238, 1995
36. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000
37. Bohlen D, Borner M, Sonntag RW, et al: Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161:1148-1152, 1999
38. Cullen MH, Stenning SP, Parkinson MC, et al: Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A Medical Research Council report. J Clin Oncol 14:1106-1113, 1996
39. Bajorin DF, Motzer RJ, Rodriguez E, et al: Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85:60-62, 1993
40. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513-1523, 2003
41. Nichols CR, Roth BJ, Williams SD, et al: No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the Testicular Cancer Intergroup Study. J Clin Oncol 10:760-765, 1992
42. Baniel J, Foster RS, Rowland RG, et al: Complications of primary retroperitoneal lymph node dissection. J Urol 152:424-427, 1994
43. Donohue JP, Foster RS: Retroperitoneal lymphadenectomy in staging and treatment: The development of nerve-sparing techniques. Urol Clin North Am 25:461-468, 1998
44. Jewett MA: Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am 17:449-456, 1990
45. Sheinfeld J: Complications of retroperitoneal lymph node dissection. AUA News 7:10-14, 2002
46. Howard GC, Clarke K, Elia MH, et al: A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours: The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists. Br J Cancer 72:1303-1306, 1995
47. Hao D, Seidel J, Brant R, et al: Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance. J Urol 160:768-771, 1998
48. Dewar JM, Spagnolo DV, Jamrozik KD, et al: Predicting relapse in stage I non-seminomatous germ cell tumours of the testis. Lancet 1:454, 1987
49. Pizzocaro G, Zanoni F, Milani A, et al: Orchiectomy alone in clinical stage I nonseminomatous testis cancer: A critical appraisal. J Clin Oncol 4:35-40, 1986
50. Sogani PC, Perrotti M, Herr HW, et al: Clinical stage I testis cancer: Long-term outcome of patients on surveillance. J Urol 159:855-858, 1998